You have heard the wild stories from your friends about their psychedelic experiences and you have finally made up your mind to also “trip.” However, after taking the substance, rather than the rollercoaster you expected to go on, there is nothing but the sound of crickets in your head. What could have happened? Experts say one of the following factors may be responsible for your lackluster reaction to psychedelics.
Taking an Inadequate Dose
The stories of how powerful psychedelics can be may scare some people so much that when they decide to take these substances, they administer a dose that is so small that it cannot allow the psychedelic drug to take full effect. This may be the reason why someone expecting to be transported to a new dimension remains firmly rooted to earth while contemplating their problems.
Other Substances in Your Body
You can also have a muted psychedelic experience if your system has other substances which affect your nervous system as well as the chemicals responsible for processing psychedelics.
For example, antidepressants in the SSRI (selective serotonin reuptake inhibitors) class can interfere with the action of psychedelics. As a result, your psychedelic trip will be less intense and it may also be a lot shorter than it would have been if you hadn’t been taking those other substances.
How Your Body Metabolizes Drugs
Two individuals taking an identical dose of the same psychedelic drug can have psychedelic experiences that are totally different in terms of their duration and intensity. This difference is often the result of variations in the way each person’s body metabolizes psychedelics.
The specific areas of the brain that are activated (and the degree to which the neural connections are activated) will also determine what kind of psychedelic experience you have. For that reason, it isn’t possible for two individuals to have exactly the same experience, unless many factors have been adjusted for as your session is planned.
Your Intention
The reasons behind your use of psychedelics could also impact how those substances affect you. For example, if someone expects physical healing, they may be less likely to experience many of the psychological effects of the psychedelic substance since they will be more tuned to the bodily changes that are likely to occur. Additionally, people who have undergone trauma or are highly intellectual by nature may indulge in some degree of self-protection. This self-protection can block some of the psychological effects of the psychedelic from manifesting.
These factors, and others at play, could be the reason why many sector players, such as Cybin Corp., encourage people to take psychedelics under the supervision of an experienced health professional.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…
The new FDA voucher program aims to speed approval of drugs aligned with national health…
The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…
The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…
Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…
Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…